HRP20161458T1 - Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze - Google Patents

Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze Download PDF

Info

Publication number
HRP20161458T1
HRP20161458T1 HRP20161458TT HRP20161458T HRP20161458T1 HR P20161458 T1 HRP20161458 T1 HR P20161458T1 HR P20161458T T HRP20161458T T HR P20161458TT HR P20161458 T HRP20161458 T HR P20161458T HR P20161458 T1 HRP20161458 T1 HR P20161458T1
Authority
HR
Croatia
Prior art keywords
seq
rv3616c protein
sequence
polypeptide
variant
Prior art date
Application number
HRP20161458TT
Other languages
English (en)
Croatian (hr)
Inventor
James Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals S.A.
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A., Glaxo Group Limited filed Critical Glaxosmithkline Biologicals S.A.
Publication of HRP20161458T1 publication Critical patent/HRP20161458T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
HRP20161458TT 2008-07-25 2009-07-24 Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze HRP20161458T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
PCT/EP2009/059580 WO2010010177A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods
EP09781052.7A EP2315773B1 (en) 2008-07-25 2009-07-24 Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis

Publications (1)

Publication Number Publication Date
HRP20161458T1 true HRP20161458T1 (hr) 2016-12-16

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161458TT HRP20161458T1 (hr) 2008-07-25 2009-07-24 Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze

Country Status (24)

Country Link
US (2) US20110117119A1 (enExample)
EP (1) EP2315773B1 (enExample)
JP (1) JP5873332B2 (enExample)
KR (1) KR20110044883A (enExample)
CN (1) CN102164952B (enExample)
AU (1) AU2009273130B2 (enExample)
BR (1) BRPI0916703A2 (enExample)
CA (1) CA2731499C (enExample)
CO (1) CO6341637A2 (enExample)
CY (1) CY1118200T1 (enExample)
DK (1) DK2315773T3 (enExample)
EA (1) EA024826B1 (enExample)
ES (1) ES2602430T3 (enExample)
HR (1) HRP20161458T1 (enExample)
HU (1) HUE031044T2 (enExample)
IL (1) IL210559A0 (enExample)
LT (1) LT2315773T (enExample)
MX (1) MX2011000983A (enExample)
PL (1) PL2315773T3 (enExample)
PT (1) PT2315773T (enExample)
SG (1) SG192456A1 (enExample)
SI (1) SI2315773T1 (enExample)
UA (1) UA107330C2 (enExample)
WO (1) WO2010010177A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941545D1 (de) * 1998-11-04 2009-11-26 Isis Innovation Tuberkulose diagnose test
HRP20181353T1 (hr) 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
NO2315597T3 (enExample) 2008-07-25 2018-01-20
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai
DK3049973T3 (en) 2013-09-27 2018-10-22 Codexis Inc AUTOMATED SCREENING OF ENZYM VARIENTS
WO2015048573A1 (en) 2013-09-27 2015-04-02 Codexis, Inc. Structure based predictive modeling
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
KR102947433B1 (ko) 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
KR20240049802A (ko) * 2021-08-31 2024-04-17 비르 바이오테크놀로지, 인코포레이티드 결핵 백신
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
BR9909472A (pt) * 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
PT2133100E (pt) * 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
AU2002219338B2 (en) * 2001-01-08 2006-12-14 Oxford Immunotec Limited Assay to determine efficacy of treatment for mycobacterial infection
US20040121322A9 (en) * 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
US7968105B2 (en) * 2005-06-23 2011-06-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai

Also Published As

Publication number Publication date
UA107330C2 (uk) 2014-12-25
US9795663B2 (en) 2017-10-24
US20140178423A1 (en) 2014-06-26
EP2315773B1 (en) 2016-08-24
ES2602430T3 (es) 2017-02-21
PL2315773T3 (pl) 2017-07-31
CY1118200T1 (el) 2017-06-28
HUE031044T2 (en) 2017-06-28
LT2315773T (lt) 2016-11-10
AU2009273130B2 (en) 2014-10-16
US20110117119A1 (en) 2011-05-19
SG192456A1 (en) 2013-08-30
CA2731499C (en) 2017-01-10
CN102164952B (zh) 2016-05-25
CO6341637A2 (es) 2011-11-21
BRPI0916703A2 (pt) 2019-12-24
MX2011000983A (es) 2011-03-02
JP2011528895A (ja) 2011-12-01
DK2315773T3 (en) 2016-12-12
PT2315773T (pt) 2016-11-23
KR20110044883A (ko) 2011-05-02
CN102164952A (zh) 2011-08-24
AU2009273130A1 (en) 2010-01-28
CA2731499A1 (en) 2010-01-28
WO2010010177A1 (en) 2010-01-28
JP5873332B2 (ja) 2016-03-01
EP2315773A1 (en) 2011-05-04
EA201100072A1 (ru) 2011-10-31
EA024826B1 (ru) 2016-10-31
SI2315773T1 (sl) 2016-12-30
IL210559A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
JP2011528896A5 (enExample)
JP2015514132A5 (enExample)
JP2011528895A5 (enExample)
PE20120425A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
HRP20150108T1 (hr) Peptidna cjepiva za rak koji eksprimira tumoru pridružene antigene
JP2006506942A5 (enExample)
JP2011528897A5 (enExample)
HRP20161608T1 (hr) Modificirani tuberkulozni antigeni
JP2010506826A5 (enExample)
HRP20161305T1 (hr) Liječenje mikrobnih infekcija
JP2015525217A5 (enExample)
JP2008529558A5 (enExample)
ATE462003T1 (de) Aus wt1 stammende krebsantigenpeptide
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
JP2008530245A5 (enExample)
JP2013513377A5 (enExample)
JP2019525753A5 (enExample)
JP2014529399A5 (enExample)
JP2008521795A5 (enExample)
JP2017536124A5 (enExample)
JP2017519763A5 (enExample)
JP2009527510A5 (enExample)
JP2009544304A5 (enExample)
JP2011530277A5 (enExample)
JP2018510213A5 (enExample)